96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B

Hui, Chee-Kin; Zhang, Hai-Ying; Bowden, Scott; Locarnini, Stephen; Luk, John M.; Leung, Kar-Wai; Yueng, Yui-Hung; Wong, April; Rousseau, Frank; Yuen, Kwok-Yung; Naoumov, Nikolai N.; Lau, George K.K.

doi:10.1016/j.jhep.2007.10.013

« Previous Next »Journal of Hepatology
Volume 48, Issue 5 , Pages 714-720, May 2008

96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B☆

Chee-Kin Hui
- Department of Microbiology, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
- Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, China
- State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong SAR, China
Hai-Ying Zhang
- Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, China
Scott Bowden
- Victorian Infectious Diseases Reference Laboratory, Vic., Australia
Stephen Locarnini
- Victorian Infectious Diseases Reference Laboratory, Vic., Australia
John M. Luk
- Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
Kar-Wai Leung
- Department of Microbiology, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
- Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, China
- State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong SAR, China
Yui-Hung Yueng
- Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, China
April Wong
- Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, China
Frank Rousseau
- Gilead Sciences Inc., Durham, NC, USA
Kwok-Yung Yuen
- Department of Microbiology, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
- Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, China
- State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong SAR, China
Nikolai N. Naoumov
- Institute of Hepatology, University College London, London, UK
George K.K. Lau
- Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, China
- Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, China
- Corresponding author. Tel.: +852 28184300; fax: +852 28184030.

Received 23 July 2007; received in revised form 8 October 2007; accepted 11 October 2007. published online 03 January 2008.

Associate Editor: F. Zoulim

To access this article, please choose from the options below

☆ F.R. is an employee of Gilead Sciences. The authors who have taken part in the research of this paper declared that they received grants from Gilead Sciences. GKK Lau received a grant from Gilead Science and RGC Grant HKU 7679/06M to carry out this study.

PII: S0168-8278(07)00653-8

doi:10.1016/j.jhep.2007.10.013

Refers to corrigendum:

Corrigendum to “96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B” J Hepatol 48 (2008) 714–720
Chee-Kin Hui, Hai-Ying Zhang, Scott Bowden, Stephen Locarnini, John M. Luk, Kar-Wai Leung, Yui-Hung Yueng, April Wong, Frank Rousseau, Kwok-Yung Yuen, Nikolai N. Naoumov, George K.K. Lau
Journal of Hepatology June 2009 (Vol. 50, Issue 6, Pages 1283-1284)
- Full Text
- PDF (65 KB)